Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention

被引：0
|
作者：
Bart M. S. Heeg
Ron J. G. Peters
Marc Botteman
Ben A. van Hout
机构：
[1] Pharmerit International,Department of Cardiology
[2] Academic Medical Centre,undefined
[3] Pharmerit International,undefined
来源：
PharmacoEconomics | 2007年 / 25卷
关键词：
Percutaneous Coronary Intervention; Clopidogrel; Clopidogrel Therapy; Elective Percutaneous Coronary Intervention; Deterministic Sensitivity Analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: The PCI-CURE (Percutaneous Coronary Intervention-Clopidogrel in Unstable Angina to Prevent Recurrent Events) and CREDO (Clopidogrel for the Reduction of Events During Observation) studies have demonstrated that, in addition to aspirin, pre-treatment with clopidogrel followed by long-term (i.e. 9—12 months) therapy significantly reduces the risk of atherothrombotic events in patients undergoing percutaneous coronary intervention (PCI).
引用
收藏
页码：769 / 782
页数：13
相关论文
共 50 条
  • [1] Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention
    Heeg, Bart M. S.
    Peters, Ron J. G.
    Botteman, Marc
    van Hout, Ben A.
    PHARMACOECONOMICS, 2007, 25 (09) : 769 - 782
  • [2] Clopidogrel discontinuation and long-term outcome after percutaneous coronary intervention
    Oemrawsingh, R. M.
    Van Domburg, R. T.
    Onuma, J.
    Van Nierop, J. W. I.
    De Jaegere, P. P. T.
    Boersma, E.
    Serruys, P. W. J. C.
    EUROPEAN HEART JOURNAL, 2010, 31 : 221 - 221
  • [3] Clopidogrel Discontinuation and Long-term Outcome After Percutaneous Coronary Intervention
    Oemrawsingh, Rohit M.
    van Domburg, Ron T.
    Onuma, Yoshinobu
    van Nierop, Josephine W.
    de Jaegere, Peter P.
    Boersma, Eric
    Serruys, Patrick W.
    CIRCULATION, 2009, 120 (18) : S970 - S970
  • [4] Clopidogrel Discontinuation And Long-term Outcome After Percutaneous Coronary Intervention
    van Domburg, Ron T.
    Onuma, Yoshinobu
    Oemrawsingh, Rohit
    van Nierop, Josephine
    de Jaegere, Peter P. P. T.
    Serruys, Patrick W.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (6A): : 172D - 172D
  • [5] Long-term clopidogrel therapy is particularly beneficial for patients requiring repeat revascularization after an initial percutaneous coronary intervention
    Saw, J
    Topol, EJ
    Steinhubl, SR
    Brennan, D
    Berger, PB
    Moliterno, DJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 50A - 50A
  • [6] Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention
    Lee, Su Nam
    Moon, Donggyu
    Sung, Min Kyung
    Moon, Keon-Woong
    Yoo, Ki-Dong
    PLATELETS, 2019, 30 (08) : 1030 - 1035
  • [7] Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?
    Ortega-Paz, Luis
    Sabate, Manel
    Angiolillo, Dominick J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (16) : 1579 - 1582
  • [8] The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention
    Akbulut, M
    Ozbay, Y
    Karaca, I
    Ilkay, E
    Gundogdu, Z
    Arslan, N
    CORONARY ARTERY DISEASE, 2004, 15 (06) : 347 - 352
  • [9] Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy
    DeEugenio, Deborah
    Kolman, Louis
    DeCaro, Matthew
    Andrel, Jocelyn
    Chervoneva, Inna
    Duong, Phu
    Lam, Linh
    McGowan, Christopher
    Lee, Grace
    DeCaro, Mark
    Ruggiero, Nicholas
    Singhal, Shalabh
    Greenspon, Arnold
    PHARMACOTHERAPY, 2007, 27 (05): : 691 - 696
  • [10] Optimal Antithrombotic Therapy in Patients Receiving Long-term Oral Anticoagulation Requiring Percutaneous Coronary Intervention "Triple Therapy" or "Triple Threat"
    Tapp, Luke D.
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    CHEST, 2011, 139 (02) : 240 - 243
12345